NR3C2 and Alzheimer disease: The administration of MR mitigated the AD-induced decline in mRNA expression of the free fatty acid receptors, FFAR2 and FFAR3, and SCFA transporter, MCT1 (p < 0.05 or p < 0.01, Figure 7C–E).